Skip to main content
Clinical Trials/NL-OMON26600
NL-OMON26600RecruitingNot Applicable

An Open-label Phase I/IIa Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or recurrent malignant glioma.

to-BBB Technologies B.V.to-BBB technologies BVNiels Bohrweg 11, 2333 CA LeidenBio Partner Center IIThe NetherlandsPhone: +31 (0) 71 3322256Fax: +31 (0) 84 8313409Email: gladdines@tobbb.com0 sites40 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

/A

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Age at least 18 years;
  • 2. Measurable or evaluable brain disease;

Exclusion Criteria

  • Prior Treatment:
  • 1. Less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy and systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), less than 8 weeks for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C;

Investigators

Sponsor
to-BBB Technologies B.V.to-BBB technologies BVNiels Bohrweg 11, 2333 CA LeidenBio Partner Center IIThe NetherlandsPhone: +31 (0) 71 3322256Fax: +31 (0) 84 8313409Email: gladdines@tobbb.com

Similar Trials

Withdrawn
Phase 1
Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS IIMucopolysaccharidosis II
NCT05238324Homology Medicines, Inc
Active, not recruiting
Phase 1
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 17.1Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-003596-35-FRGlaxoSmithKline Research & Development Ltd94
Active, not recruiting
Phase 1
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with CancerChildren and Adolescents with Cancers Harboring V600 mutationsMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-003596-35-GBovartis Pharma Services AG145
Active, not recruiting
Phase 1
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias
EUCTR2009-017376-25-BEGlaxoSmithKline Research & Development Ltd135
Active, not recruiting
Not Applicable
A phase 1/II study to investigate how the drug GSK1120212 behaves, its safety and effectiveness in subjects with cancer of blood cellsRelapsed or refractory leukemiasMedDRA version: 14.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-017376-25-DEGlaxoSmithKline Research & Development Ltd135